{"doi":"10.1001/jamanetworkopen.2021.40858","title":"Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis","abstract":null,"journal":"JAMA Network Open","year":2021,"id":630414,"datarank":0.515098080672772,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"self_citation_contribution":0.515098080672772,"citation_network_contribution":0.0,"self_endowment_contribution":0.515098080672772,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1633165,"name":"Dominic Stringer","orcid":null,"position":1,"is_corresponding":false},{"id":1633166,"name":"Gabriella Wojewodka","orcid":null,"position":2,"is_corresponding":false},{"id":1593979,"name":"Sabine Landau","orcid":"0000-0002-3615-8075","position":3,"is_corresponding":false},{"id":1633167,"name":"Shubulade Smith","orcid":null,"position":4,"is_corresponding":false},{"id":1633168,"name":"Poonam Gardner-Sood","orcid":null,"position":5,"is_corresponding":false},{"id":283012,"name":"David Taylor","orcid":"0000-0002-2557-1710","position":6,"is_corresponding":false},{"id":1633169,"name":"Harriet Jordan","orcid":null,"position":7,"is_corresponding":false},{"id":1633170,"name":"Eromona Whiskey","orcid":null,"position":8,"is_corresponding":false},{"id":1633171,"name":"Amir Krivoy","orcid":null,"position":9,"is_corresponding":false},{"id":557363,"name":"Simone Ciufolini","orcid":"0000-0002-1968-5041","position":10,"is_corresponding":false},{"id":680,"name":"Brendon Stubbs","orcid":"0000-0001-7387-3791","position":11,"is_corresponding":false},{"id":979921,"name":"Cecilia Casetta","orcid":"0000-0002-1980-3415","position":12,"is_corresponding":false},{"id":593627,"name":"Julie Williams","orcid":"0000-0002-6209-4431","position":13,"is_corresponding":false},{"id":874716,"name":"Susan Moore","orcid":"0000-0002-7226-6444","position":14,"is_corresponding":false},{"id":764825,"name":"Lauren Allen","orcid":"0000-0003-1846-8181","position":15,"is_corresponding":false},{"id":1633173,"name":"Shanaya Rathod","orcid":null,"position":16,"is_corresponding":false},{"id":1633174,"name":"Andrew Boardman","orcid":null,"position":17,"is_corresponding":false},{"id":1633175,"name":"Rehab Khalifa","orcid":null,"position":18,"is_corresponding":false},{"id":1633176,"name":"Mudasir Firdosi","orcid":null,"position":19,"is_corresponding":false},{"id":34668,"name":"Philip McGuire","orcid":"0000-0003-4381-0532","position":20,"is_corresponding":false},{"id":56340,"name":"Michael Berk","orcid":"0000-0002-5554-6946","position":21,"is_corresponding":false},{"id":42817,"name":"John McGrath","orcid":null,"position":22,"is_corresponding":false},{"id":573929,"name":"Fiona Gaughran","orcid":"0000-0001-7414-5569","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis","abstract":"Importance: People with psychotic disorders have an increased risk of vitamin D deficiency, which is evident during first-episode psychosis (FEP) and associated with unfavorable mental and physical health outcomes. Objective: To examine whether vitamin D supplementation contributes to improved clinical outcomes in FEP. Design, Setting, and Participants: This multisite, double-blind, placebo-controlled, parallel-group randomized clinical trial from the UK examined adults 18 to 65 years of age within 3 years of a first presentation with a functional psychotic disorder who had no contraindication to vitamin D supplementation. A total of 2136 patients were assessed for eligibility, 835 were approached, 686 declined participation or were excluded, 149 were randomized, and 104 were followed up at 6 months. The study recruited participants from January 19, 2016, to June 14, 2019, with the final follow-up (after the last dose) completed on December 20, 2019. Interventions: Monthly augmentation with 120 000 IU of cholecalciferol or placebo. Main Outcomes and Measures: The primary outcome measure was total Positive and Negative Syndrome Scale (PANSS) score at 6 months. Secondary outcomes included total PANSS score at 3 months; PANSS positive, negative, and general psychopathology subscale scores at 3 and 6 months; Global Assessment of Function scores (for symptoms and disability); Calgary Depression Scale score, waist circumference, body mass index, and glycated hemoglobin, total cholesterol, C-reactive protein, and vitamin D concentrations at 6 months; and a planned sensitivity analysis in those with insufficient vitamin D levels at baseline. Results: A total of 149 participants (mean [SD] age, 28.1 (8.5) years; 89 [59.7%] male; 65 [43.6%] Black or of other minoritized racial and ethnic group; 84 [56.4%] White [British, Irish, or of other White ethnicity]) were randomized. No differences were observed in the intention-to-treat analysis in the primary outcome, total PANSS score at 6 months (mean difference, 3.57; 95% CI, -1.11 to 8.25; P = .13), or the secondary outcomes at 3 and 6 months (PANSS positive subscore: mean difference, -0.98; 95% CI, -2.23 to 0.27 at 3 months; mean difference, 0.68; 95% CI, -0.69 to 1.99 at 6 months; PANSS negative subscore: mean difference, 0.68; 95% CI, -1.39 to 2.76 at 3 months; mean difference, 1.56; 95% CI, -0.31 to 3.44 at 6 months; and general psychopathology subscore: mean difference, -2.09; 95% CI, -4.36 to 0.18 at 3 months; mean difference, 1.31; 95% CI, -1.42 to 4.05 at 6 months). There also were no significant differences in the Global Assessment of Function symptom score (mean difference, 0.02; 95% CI, -4.60 to 4.94); Global Assessment of Function disability score (mean difference, -0.01; 95% CI, -5.25 to 5.23), or Calgary Depression Scale score (mean difference, -0.39; 95% CI, -2.05 to 1.26) at 6 months. Vitamin D levels were very low in the study group, especially in Black participants and those who identified as another minoritized racial and ethnic group, 57 of 61 (93.4%) of whom had insufficient vitamin D. The treatment was safe and led to a significant increase in 25-hydroxyvitamin D concentrations. Conclusions and Relevance: In this randomized clinical trial, no association was found between vitamin D supplementation and mental health or metabolic outcomes at 6 months. Because so few patients with FEP were vitamin D replete, the results of this study suggest that this group would benefit from active consideration in future population health strategies. Trial Registration: isrctn.org Identifier: ISRCTN12424842.","is_dataset_classified":null,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34962559","pmcid":"PMC8715346","openalex_id":"https://openalex.org/W4200572555","authors":[],"funders":[{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"NIHR301206","title":null},{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"ICA-CL-2017-03-001","title":null}],"total_grants":2,"fwci":2.9871,"citation_percentile":0.921802,"influential_citations":0,"citation_trend":[{"year":2022,"count":4},{"year":2023,"count":9},{"year":2024,"count":8},{"year":2025,"count":5},{"year":2026,"count":4}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787456/gaughran_2021_oi_211145_1639690947.56235.pdf","host_type":"journal"},{"url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787456/gaughran_2021_oi_211145_1639690947.56235.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1001/jamanetworkopen.2021.40858","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34962559","host_type":"repository"},{"url":"https://kclpure.kcl.ac.uk/portal/en/publications/1b887c2f-f1c2-4120-9322-e6a3e4821f0a","host_type":"repository"},{"url":"https://pure.au.dk/portal/en/publications/15417a0e-ee6d-42a9-b6cd-480e294b2e8b","host_type":""},{"url":"http://doi.org/10.1001/jamanetworkopen.2021.40858","host_type":"repository"},{"url":"https://figshare.com/articles/journal_contribution/Effect_of_Vitamin_D_Supplementation_on_Outcomes_in_People_with_Early_Psychosis_The_DFEND_Randomized_Clinical_Trial/20627022","host_type":"repository"},{"url":"https://kar.kent.ac.uk/97552/","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8715346","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8715346","host_type":"Europe_PMC"}],"fields_of_study":["Vitamin D Research Studies","Tryptophan and brain disorders","Vitamin C and Antioxidants Research"],"mesh_terms":["Adolescent","Adult","Aged","Double-Blind Method","Female","United Kingdom","Humans","Male","Middle Aged","Psychotic Disorders","Vitamin D","Vitamin D Deficiency"],"keywords":["Psychosis","Psychology","Vitamin","Vitamin D and neurology","Psychiatry","Medicine","Gerontology","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"omim"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T21:13:33.016295Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}